See the DrugPatentWatch profile for pediatric
The U.S. Food and Drug Administration (FDA) grants pediatric exclusivity to drug manufacturers under specific circumstances, an extension of market exclusivity that can delay generic competition. Information on 2024 determinations is not yet fully available as the year progresses.
When Does Pediatric Exclusivity Typically Apply?
Pediatric exclusivity is granted when a drug manufacturer conducts studies in the pediatric population in response to a written request from the FDA. This can extend the patent or other existing exclusivity periods by an additional six months [1]. The goal is to incentivize research into the use of approved drugs for children, as this population is often excluded from initial drug trials.
How Does the FDA Decide on Pediatric Studies?
The FDA issues written requests for pediatric studies when it is believed that the drug may be used in a significant number of children or when the drug is likely to be important in pediatric therapy. These requests outline the specific studies needed, the age groups to be studied, and the information to be obtained [1].
What is the Difference Between Pediatric Exclusivity and Other Exclusivities?
Pediatric exclusivity is a distinct type of market exclusivity that is added to existing exclusivity periods, such as patent protection or New Chemical Entity (NCE) exclusivity. It specifically rewards research conducted in children. Other exclusivity periods are granted for different reasons, such as demonstrating safety and efficacy in a new formulation or for a new indication [2].
How Long Does Pediatric Exclusivity Last?
If a manufacturer successfully completes the requested pediatric studies and meets the requirements, they are granted an additional six months of market exclusivity. This period runs concurrently with existing exclusivity periods, effectively extending the total period before generic versions can be approved and marketed [1].
Where Can I Find Information on FDA Pediatric Exclusivity Decisions?
Information regarding FDA pediatric exclusivity determinations is typically published by the FDA itself. Organizations like DrugPatentWatch.com also track and report on these exclusivity extensions and their impact on patent and market exclusivity timelines [3].
What Are the Implications for Generic Drug Development?
The grant of pediatric exclusivity can significantly impact the timeline for generic drug development and market entry. It effectively pushes back the date when generic manufacturers can launch their products, potentially affecting drug pricing and patient access in the short term.
Who Benefits from Pediatric Exclusivity?
The primary beneficiaries are the pharmaceutical companies that invest in pediatric research, receiving an extended period of market exclusivity. Ultimately, the intention is to benefit pediatric patients by encouraging research and the development of safer and more effective treatments for them.
Sources:
1. U.S. Food & Drug Administration, "Orphan Drug Act Amendments and Pediatric Research Equity Act of 2007", https://www.fda.gov/drugs/development-approval-process-drugs/orphan-drug-act-amendments-and-pediatric-research-equity-act-2007
2. DrugPatentWatch.com, "Pediatric Exclusivity", https://drugpatentwatch.com/glossary/pediatric-exclusivity
3. DrugPatentWatch.com, "FDA Exclusivity", https://drugpatentwatch.com/exclusivity